What is the new partnership between John Wiley & Sons and IQVIA?

John Wiley & Sons and IQVIA have partnered to offer a unified solution for Clinical Outcome Assessment (COA) execution, simplifying licensing and implementation for research.

How does the Wiley-IQVIA collaboration simplify clinical trials?

It consolidates COA licensing and implementation into one contract, eliminating the need for multiple vendors and reducing trial timelines.

What COA tools are available through Wiley's partnership with IQVIA?

Initially, five Wiley-managed COA tools are offered, with plans to expand to over 100 COAs and full lifecycle services by late 2026.

Home / Business and Economy / Wiley Partners with IQVIA for Streamlined Clinical Trials

Wiley Partners with IQVIA for Streamlined Clinical Trials

9 Dec, 2025

•

Summary

Wiley and IQVIA formed a partnership for COA execution.
The collaboration simplifies complex COA licensing and implementation.
Phase one offers five Wiley COA tools as complete solutions.

Wiley Partners with IQVIA for Streamlined Clinical Trials

John Wiley & Sons, Inc. has entered a significant partnership with IQVIA Holdings Inc. aimed at simplifying Clinical Outcome Assessment (COA) execution. This collaboration addresses the historically complex and time-consuming process of COA licensing, which usually requires managing multiple vendors for instruments, translation, and implementation.

The new integrated solution provides pharmaceutical and research organizations with a streamlined, single-contract approach. This simplifies workflows, enhances quality assurance, and ensures scientific accuracy and copyright protection, significantly reducing potential trial delays and compliance issues.

Phase one of this initiative offers five Wiley-managed COA tools as complete packages. The plan is to broaden this offering by the end of 2026 to include Wiley's extensive catalog of over 100 COAs, complete with full lifecycle services.